Finance

Lists
Why is OBIO up 3,84%?
Dive Deeper
OBIO:NASDAQ
Orchestra Biomed Holdings Inc
USD 5,95
+3,84%
(+0,22) 1D
9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OBIO...
Open
USD 5,73
High
USD 5,96
Low
USD 5,56
Mkt. cap
357,62 m
Avg. vol.
338,94 k
Volume
0,00
52-wk high
USD 6,50
52-wk low
USD 2,86
EPS
-USD 1,01
Beta
0,52
Shares outstanding
60,10 m
No. of employees
86
Open
USD 5,73
High
USD 5,96
Low
USD 5,56
Mkt. cap
357,62 m
Avg. vol.
338,94 k
Volume
0,00
52-wk high
USD 6,50
52-wk low
USD 2,86
EPS
-USD 1,01
Beta
0,52
Shares outstanding
60,10 m
No. of employees
86
News stories
From web sources and news partners
About Orchestra Biomed Holdings Inc
CEO-
Employees86
Founded2018
Headquarters-
SectorMedical device
Websiteorchestrabiomed.com
Analyst ratings
Based on 5 analysts giving stock ratings to OBIO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OBIO in the last 3 months.
Highest
Current USD 5,95
USD 15,00 (+152,10%)
Average
USD 11,20 (+88,24%)
Lowest
USD 10,00 (+68,07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
USD 10,00
+68,1%
10/05/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
USD 11,00
+84,9%
10/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
USD 15,00
+152,1%
09/25/2026
Marie Thibault
BTIG
Buy
Upgraded
USD 10,00
+68,1%
09/10/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
USD 10,00
+68,1%
08/11/2026
Unknown Analyst
BTIG
Hold
Maintained
-
-
07/09/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
USD 10,00
+68,1%
05/18/2026
Matt Miksic
Barclays
Buy
Reiterated
USD 13,00
+118,5%
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
USD 20,00
+236,1%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
861,00 k
30,92 m
110,00 k
88,00 k
Cost of goods sold
49,00 k
51,00 k
32,00 k
25,00 k
Cost of revenue
49,00 k
51,00 k
32,00 k
25,00 k
Research and development expenses
14,03 m
16,82 m
15,78 m
16,59 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,10 m
7,29 m
6,37 m
5,83 m
Operating expense
21,12 m
24,11 m
22,15 m
22,42 m
Total operating expenses
21,17 m
24,16 m
22,19 m
22,44 m
Operating income
-20,31 m
6,75 m
-22,08 m
-22,36 m
Other non operating income
-
254,00 k
-376,00 k
-517,00 k
EBT including unusual items
-20,83 m
6,24 m
-20,69 m
-23,76 m
EBT excluding unusual items
-20,83 m
6,24 m
-22,93 m
-23,80 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,83 m
6,24 m
-20,69 m
-23,76 m
Net profit margin
-2 419,05%
20,20%
-18 810,00%
-26 994,32%
Earnings per share
-0,40
0,26
-0,33
-0,37
Interest and investment income
-
752,00 k
-
-
Interest expense
-515,00 k
-1,52 m
-480,00 k
-927,00 k
Net interest expenses
-515,00 k
-763,00 k
-480,00 k
-927,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,23 m
6,84 m
-21,99 m
-22,26 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme